Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 2/20 | 0.44 |
| ▸ | F3 | P13726 | 2/20 | 0.44 |
| ▸ | AHR | P35869 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9305060 | 0.84 | ALDH1A1 (0.61) | ALDH1A1HTR3EHTR3BHTR3ABACE1 | |
| SCHEMBL1192946 | 0.79 | F7 (0.47) | F7F3AHRLTA4HNR4A2 | |
| SCHEMBL4483413 | 0.79 | NOS1 (0.44) | AHRNR4A2ALDH1A1BACE1NOS1 | |
| SCHEMBL1171146 | 0.79 | ALDH1A1 (0.53) | F7F3AHRLTA4HNR4A2 | |
| SCHEMBL482225 | 0.76 | F7 (0.44) | F7F3AHRLTA4HNR4A2 | |
| SCHEMBL4794109 | 0.76 | F7 (0.44) | F7F3AHRLTA4HNR4A2 | |
| SCHEMBL216615 | 0.76 | HTR3E (0.72) | F7F3AHRLTA4HNR4A2 | |
| SCHEMBL22955322 | 0.76 | ALPL (0.40) | AHRALDH1A1HPGDSMN1; SMN2TDP1 | |
| SCHEMBL2884818 | 0.76 | ALDH1A1 (0.72) | F7F3AHRLTA4HNR4A2 | |
| SCHEMBL29824694 | 0.76 | ALPL (0.40) | AHRALDH1A1HPGDSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125348-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | OREGON STATE UNIVERSITY (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4710922-A2 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | Oregon State University (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4003337-B1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | UNIV OREGON STATE (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12473262-B2 | Aryl hydrocarbon receptor activators | OREGON STATE UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20220281824-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | OREGON STATE UNIVERSITY (US) | 2022-09-08 | — | — | US | disclosed |
| EP-4003337-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | Oregon State University (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021022061-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | OREGON STATE UNIVERSITY (US) | 2021-02-04 | — | — | WO | disclosed |
| US-10882850-B2 | Organic compound with triazine and benzimidazole as core and application thereof in organic electroluminescent device | JIANGSU SUNERA TECHNOLOGY CO., LTD (CN) | 2021-01-05 | — | — | US | disclosed |
| US-10882850-B2 | Organic compound with triazine and benzimidazole as core and application thereof in organic electroluminescent device | JIANGSU SUNERA TECHNOLOGY CO., LTD (CN) | 2021-01-05 | — | — | US | disclosed |
| US-20190071430-A1 | Organic Compound with Triazine and Benzimidazole as Core and Application thereof in Organic Electroluminescent Device | Jiangsu Sunera Technology Co.,Ltd (CN) | 2019-03-07 | — | — | US | disclosed |
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-20140378525-A1 | MATERIALS AND METHODS FOR TREATING PTEN MUTATED OR DEFICIENT CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2014-12-25 | — | — | US | disclosed |
| WO-2014176258-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014176258-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-30 | — | — | WO | disclosed |
| US-5347008-A | Thio(cyclo) alkanepolycarboxylic acids containing heterocyclic substituents | CIBA-GEIGY CORPORATION (US) | 1994-09-13 | — | — | US | disclosed |
| US-5152929-A | Corrosion inhibitors for water systems | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0129506-A2 | Heterocyclically substituted thio(cyclo)alkane polycarboxylic acids | CIBA-GEIGY AG (CH) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281824-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | AHR, ARNT, NR0B1 | F7 4859/4885F3 3054/4885AHR 1/4885 |
| US-20190071430-A1 | Organic Compound with Triazine and Benzimidazole as Core and Application thereof in Organic Electroluminescent Device | BRD4, BRD7, BRD3 | F7 1461/4885F3 1530/4885AHR 13/4885 |
| US-20140378525-A1 | MATERIALS AND METHODS FOR TREATING PTEN MUTATED OR DEFICIENT CANCER | BUB1B, TTK, BUB1 | F7 4214/4885F3 4254/4885AHR 4807/4885 |
| US-10882850-B2 | Organic compound with triazine and benzimidazole as core and application thereof in organic electroluminescent device | BRD4, BRD7, BRD3 | F7 1461/4885F3 1530/4885AHR 13/4885 |
| US-20260125348-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | AHR, ARNT, NR1H2 | F7 2352/4885F3 1288/4885AHR 1/4885 |
| US-12473262-B2 | Aryl hydrocarbon receptor activators | AHR, ARNT, NR0B1 | F7 4859/4885F3 3054/4885AHR 1/4885 |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | CFTR, SLC11A2, MRPS18A | F7 102/4885F3 90/4885AHR 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.